Skip to main content
. Author manuscript; available in PMC: 2009 Nov 1.
Published in final edited form as: Clin Cancer Res. 2008 Nov 1;14(21):6790–6796. doi: 10.1158/1078-0432.CCR-08-1013

Figure 4. EZH2 depletion affects pancreatic cancer chemoresistance.

Figure 4

A, Panc04.03 and SU86.86 pancreatic cancer cells were treated with DW (control), 1 μmol/L Doxorubicin (DOX) or 100 nmol/L Gemcitabine (GEM) for 24 hours. Nuclear and cytosolic fractions were prepared, separated by SDS-PAGE (50μg/well), transferred to PVDF membrane, and probed with the indicated antibodies. (B-C), Panc04.03 (B) and SU86.86 (C) pancreatic cancer cells were treated with DW (control), Doxorubicin (1 μmol/L) or Gemcitabine (100 nmol/L) for 48 hours. Whole cell lysates were prepared, separated by SDS-PAGE (50μg/well), transferred to PVDF membrane, and immunoblotted as indicated. The percentage of apoptotic cells was determined by Hoechst staining as previously described (31). Columns, mean; bars, SD.